I. Medical Device Registration Process and Classification
1. Classification and Pathway Selection
Class I (Low Risk): such as elastic bandages, typically only requires completion of Establishment Registration and Device Listing, with no premarket submission required.
Class II (Moderate Risk): such as blood glucose meters, requires a 510(k) Premarket Notification, demonstrating "substantial equivalence" to a legally marketed predicate device. In 2025, certain clinical electronic thermometers with limited functionality (no remote/continuous temperature monitoring) were exempted from 510(k), though listing and compliance with standards such as ISO 80601 remain required.
Class III (High Risk): such as artificial hearts, requires submission of a PMA (Premarket Approval Application), including comprehensive clinical data. In 2025, FDA down-classified 17 Class III devices to Class II, streamlining the market entry process for certain products.
2. Core Registration Steps
Establishment Registration and Device Listing: Submit establishment information through the FDA Unified Registration and Listing System (FURLS 2.0), including DUNS number, U.S. Agent (mandatory for foreign establishments), etc. The 2025 annual establishment registration fee is $9,280, with renewal required between October 1 and December 31 each year; late renewal may incur fines of $15,000/month。
Premarket Submission：
510(k): Fee is $24,335 ($6,084 for small businesses), with an average review cycle of 3-6 months. Technical documentation, performance data, and comparative analysis with the predicate device must be submitted.
PMA: Higher fees (specific amount not publicly disclosed), requiring multi-center clinical trial data, with review cycles potentially exceeding 1 year.
Labeling and Post-Market Surveillance: Labeling must comply with 21 CFR 801 requirements, including risk warnings and instructions for use. Post-market adverse event reports must be submitted through the MAUDE database, and registration information must be updated periodically.
II. Pharmaceutical and Biologic Registration
1. New Drug (NDA) and Generic Drug (ANDA)
NDA (New Drug Application): Requires completion of Phase I-III clinical trials and submission of CTD format documents (including CMC, non-clinical, and clinical data). In 2025, FDA introduced the Commissioner's National Priority Voucher (CNPV), allowing drugs aligned with national health priorities (such as unmet needs, innovative therapies) to shorten review time from 10-12 months to 1-2 months, provided CMC and draft labeling are submitted 60 days in advance.
ANDA (Abbreviated New Drug Application): Requires demonstration of bioequivalence to the reference listed drug (BE study) and patent challenge (Paragraph IV certification). Costs approximately $1 million, with a review cycle of 6-12 months.
2. Biologics (BLA)
BLA (Biologics License Application): Applicable to vaccines, blood products, etc., requiring submission of manufacturing process, immunogenicity data, and clinical trial results. Biosimilars follow a streamlined review via the 351(k) pathway but must demonstrate "high similarity" to the reference product.
Accelerated Approval: For products addressing serious conditions with unmet needs, approval may be based on surrogate endpoints, with subsequent verification of clinical benefit required.
III. Special Requirements for International Establishments
1. U.S. Agent and Facility Inspections
U.S. Agent: Foreign establishments must designate a U.S.-based agent responsible for communicating with FDA and receiving notifications. The agent must sign FDA Form 3674 and be linked to the establishment registration in the FURLS system.
On-Site Inspection: FDA conducts unannounced inspections of foreign facilities (e.g., in China, India), focusing on GMP compliance. In 2025, FDA expanded its inspection scope; establishments must ensure complete production records, compliant equipment maintenance, and avoid data falsification or process gaps.
2. Fee Payment and Compliance
Fee Schedule: FY2025 510(k) application fee is $24,335, and annual establishment registration fee is $9,280. Fees must be paid in USD through the FDA User Fee System, accepting credit cards (VISA / MasterCard / American Express) or wire transfer (PIN number required)。
Tax and Foreign Exchange: International establishments must handle foreign exchange control issues independently; payment through platforms such as PayPal is recommended to reduce risk. FDA currently does not explicitly require additional tax filings, but payment records should be retained for audit。
IV. Digital Tools and Policy Updates
1. AI-Assisted Review (Elsa)
2. Classification and Exemption Dynamics
Classification Adjustment: In 2025, certain Class III devices were down-classified to Class II, such as specific cardiovascular devices; establishments must reassess product classification codes (e.g., SDV) and update listings accordingly.
Exemption Policy: Beyond electronic thermometers, certain low-risk devices (such as household devices without remote functionality) may gradually be added to the exemption list; establishments can check the latest classification database on the FDA website.
V. Key Timelines and Recommendations
Registration Timeline：
Medical Devices: Class I (1-3 months), Class II (510(k) 3-6 months), Class III (PMA 12-18 months).
Pharmaceuticals: NDA (10-12 months, CNPV shortens to 1-2 months), ANDA (6-12 months).
Recommendations：
Advance Planning: Integrate compliance requirements from the R&D stage, such as label design, data recording, etc.
Professional Support: For complex applications (such as PMA, CNPV), engaging legal counsel or consulting firms is recommended to ensure documentation completeness and compliance.
Dynamic Monitoring: Monitor FDA website and industry guidance updates, such as AI tools, classification adjustments, and fee changes introduced in 2025。